Online citations, reference lists, and bibliographies.
← Back to Search

Improved Outcomes With Modern Lung‐Sparing Trimodality Therapy In Patients With Malignant Pleural Mesothelioma

F. Shaikh, Marjorie G. Zauderer, Donata von Reibnitz, A. Wu, E. Yorke, Amanda L. Foster, W. Shi, Z. Zhang, P. Adusumilli, Kenneth E. Rosenzweig, L. Krug, V. Rusch, A. Rimner
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction: Higher target conformity and better sparing of organs at risk with modern radiotherapy (RT) may result in higher tumor control and less toxicity. In this study, we compare our institutional multimodality therapy experience of adjuvant chemotherapy and hemithoracic intensity‐modulated pleural RT (IMPRINT) with previously used adjuvant conventional RT (CONV) in patients with malignant pleural mesothelioma (MPM) treated with lung‐sparing pleurectomy/decortication (P/D). Methods: We analyzed 209 patients who underwent P/D and adjuvant RT (131 who received CONV and 78 who received IMPRINT) for MPM between 1974 and 2015. The primary end point was overall survival (OS). The Kaplan‐Meier method and Cox proportional hazards model were used to calculate OS; competing risks analysis was performed for local failure‐free survival and progression‐free survival. Univariate analysis and multivariate analysis were performed with relevant clinical and treatment factors. Results: The median age was 64 years, and 80% of the patients were male. Patients receiving IMPRINT had significantly higher rates of the epithelial histological type, advanced pathological stage, and chemotherapy treatment. OS was significantly higher after IMPRINT (median 20.2 versus 12.3 months, p = 0.001). Higher Karnofsky performance score, epithelioid histological type, macroscopically complete resection, and use of chemotherapy/IMPRINT were found to be significant factors for longer OS in multivariate analysis. No significant predictive factors were identified for local failure or progression. Grade 2 or higher esophagitis developed in fewer patients after IMPRINT than after CONV (23% versus 47%). Conclusions: Trimodality therapy including adjuvant hemithoracic IMPRINT, chemotherapy, and P/D is associated with promising OS rates and decreased toxicity in patients with MPM. Dose constraints should be applied vigilantly to minimize serious adverse events.
This paper references
10.1200/JCO.2016.67.2675
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
A. Rimner (2016)
10.1016/J.IJROBP.2005.03.041
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.
V. Gupta (2005)
10.1097/JTO.0b013e3182208e3f
Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
D. Rice (2011)
Phase II study of hemithoracic intensity - modulated pleural radiation therapy ( IMPRINT ) as part of lung - sparing multimodality therapy in patients with malignant pleural mesotheli
A Rimner (2016)
10.1016/j.jtcvs.2014.03.011
Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality.
B. Burt (2014)
Volumetric-modulated arc therapy for malignant pleural mesothelioma after pleurectomy / decortication
V. Dumane (2016)
10.1186/s13014-015-0575-5
Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy
C. Thieke (2015)
10.1097/JTO.0b013e31827740f0
Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma
D. Gomez (2013)
Pleural intensity-modulated radiation therapy (imrt) for malignant pleural mesothelioma (MPM)
KE Rosenzweig (2012)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.1016/j.ijrobp.2014.05.032
Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.
A. Rimner (2014)
10.1097/JTO.0b013e3182199819
Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined-Modality Treatment of Malignant Pleural Mesothelioma
A. Chi (2011)
10.1016/j.ijrobp.2011.11.057
Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.
P. Patel (2012)
10.1016/j.jtcvs.2015.09.121
Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.
H. Batırel (2016)
Impact of intensitymodulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial
SG Chun (2017)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1200/JCO.2016.69.1378
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
S. Chun (2017)
10.1016/j.ijrobp.2011.09.027
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
K. Rosenzweig (2012)
Intensity-modulated radiotherapy after extrapleural pneumonectomy in the 1000 Shaikh et al Journal of Thoracic Oncology Vol. 12 No. 6 combined-modality treatment of malignant pleural mesothelioma
A Chi (2011)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1016/j.radonc.2011.09.025
Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series.
S. Tonoli (2011)
10.1371/journal.pone.0145039
Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients
E. Taioli (2015)
Extrapleural pneumonectomy or pleur - ectomy / decortication for malignant pleural mesotheli
S Hasegawa (2014)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/0360-3016(87)90173-8
Technique for external beam treatment for mesothelioma.
G. Kutcher (1987)
10.1016/j.ijrobp.2007.11.011
Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.
E. Miles (2008)
10.1007/s11748-014-0389-7
Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma
S. Hasegawa (2014)
10.1016/j.lungcan.2013.10.013
Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up.
E. Minatel (2014)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1016/j.ijrobp.2015.06.029
Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.
E. Minatel (2015)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)



This paper is referenced by
10.21037/atm.2017.06.25
Malignant pleural mesothelioma: adjuvant therapy with radiation therapy.
K. Rosenzweig (2017)
10.21037/tlcr-19-488
Does size matter? -a population-based analysis of malignant pleural mesothelioma.
J. He (2020)
10.1016/j.prro.2020.02.007
Disease-Related Outcomes and Toxicities of Intensity-Modulated Radiation Therapy Following Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review.
Roshal R Patel (2020)
10.1016/J.JTCVS.2019.04.050
Commentary: Return to intended radiation therapy-Criteria for resection?
Joseph Dux (2019)
10.1007/s00330-018-5937-6
Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy
D. Halpenny (2018)
10.1097/PAS.0000000000001416
Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting
Y. Z. Zhang (2020)
10.1007/978-3-030-16884-1_14
Role of Radiotherapy in Malignant Pleural Mesothelioma
M. Scorsetti (2019)
10.1016/j.jtho.2018.02.021
Progress in the Management of Malignant Pleural Mesothelioma in 2017
Amanda J McCambridge (2018)
10.3892/mco.2018.1650
Double cancer comprising malignant pleural mesothelioma and squamous cell carcinoma of the lung treated with radiotherapy: A case report.
Y. Negi (2018)
A narrative review of current treatment strategies and emerging therapies in malignant pleural mesothelioma
Élise Di Lena (2020)
10.1016/j.jtho.2018.02.021
State of the Art : Advances in Malignant Pleural Mesothelioma in 2017
Amanda J McCambridge (2018)
10.3857/roj.2019.00150
Preliminary results of entire pleural intensity-modulated radiotherapy in a neoadjuvant setting for resectable malignant mesothelioma
J. H. Hong (2019)
10.1016/S1470-2045(17)30459-X
Radiotherapy for the treatment of malignant pleural mesothelioma.
M. Perrot (2017)
Intensity Modulated Radiotherapy ( IMRT ) of the Thorax Effective : October 1 , 2018
(2018)
10.1080/17476348.2019.1679119
Types of surgery post-neoadjuvant chemotherapy for pleural mesothelioma
K. Kuribayashi (2019)
10.1007/s00066-019-01458-1
Tomotherapy in malignant mesothelioma: a planning study to establish dose constraints
C. Leitzen (2019)
10.1016/J.THORSURG.2020.08.006
Radiation Therapy for Malignant Pleural Mesothelioma.
K. Rosenzweig (2020)
10.1007/978-3-319-96244-3
Caring for Patients with Mesothelioma: Principles and Guidelines
M. Hesdorffer (2019)
10.1007/978-3-319-96244-3_17
Understanding Clinical Trials in Malignant Mesothelioma
A. Mansfield (2019)
10.1016/j.prro.2020.06.003
RapidPlan for Knowledge-Based Planning of Malignant Pleural Mesothelioma.
V. Dumane (2020)
10.1016/j.prro.2018.12.008
Dosimetric Correlates of Pulmonary Toxicity in Patients with Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs.
M. Thompson (2019)
10.1016/j.jtcvs.2019.11.035
Preoperative prediction of unresectability in malignant pleural mesothelioma.
B. Burt (2019)
10.1016/j.radonc.2017.08.003
The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.
M. Ashton (2017)
10.1007/978-3-319-52619-5_36-1
Radiation Therapy in Mesothelioma
J. Willmann (2019)
10.1016/j.jtho.2017.04.013
Pleural IMRT after Lung-Sparing Cytoreduction for Mesothelioma: Mature Enough to Randomize.
H. Pass (2017)
10.1016/j.athoracsur.2018.09.019
Differential Survival Characteristics of Sarcomatoid Subtype in Biphasic Pleural Mesothelioma.
L. Harling (2019)
10.21037/jtd.2018.01.154
The expanding role of radiation therapy for thymic malignancies.
J. Willmann (2018)
Semantic Scholar Logo Some data provided by SemanticScholar